Rafael Holdings, Inc.
Rafael Holdings exhibits a capital structure with a current ratio of 3.44, indicating strong liquidity, supported by $37.78 million in cash and equivalents as of January 31, 2026. The company's price-to-book ratio of 1.04 and price-to-tangible-book ratio of 1.04 suggest that the market values the company close to its book value, with no debt-to-equity leverage. Profitability metrics are negative, with a return on equity of -20.5% and return on assets of -16.34%, reflecting significant operational losses. The company reported a net loss of $16.23 million for the six months ended January 31, 2026, with operating income of -$16.80 million. These figures fall below the industry median for profitability, indicating underperformance relative to peers. The company's revenue is concentrated in a few segments, with the majority derived from product revenue and rental services. The six months ended January 31, 2026, saw total revenue of $451,000, with no significant geographic diversification disclosed in the financial statements. Growth trajectory is negative, with a year-over-year revenue decline. The six months ended January 31, 2026, reported $451,000 in revenue, compared to $205,000 in the same period in 2025. The outlook for the current fiscal year indicates continued challenges, with no significant revenue growth expected. Risk factors include medium dilution potential, with source documents mentioning dilution or offering risk. The company's liquidity risk is low, but the negative operating cash flow of -$14.33 million and free cash flow of -$14.33 million for the six months ended January 31, 2026, suggest ongoing cash flow challenges. Recent events include the filing of unaudited consolidated financial statements for Q2 2026, which show continued operational losses and cash flow outflows. The company also reported cash and equivalents of $37.78 million as of January 31, 2026, down from $45.54 million as of October 31, 2025.
Business. Rafael Holdings, Inc. operates in the pharmaceuticals industry, primarily through its subsidiary Day Three, which provides technology to third-party manufacturers to enhance their product offerings.
Classification. Rafael Holdings is classified under the Pharmaceuticals industry within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.78.
- Rafael Holdings has a strong liquidity position with a current ratio of 3.44 and $37.78 million in cash and equivalents.
- The company is unprofitable, with a return on equity of -20.5% and a net loss of $16.23 million for the six months ended January 31, 2026.
- Revenue is concentrated in a few segments, with no significant geographic diversification.
- The company faces medium dilution risk and has negative operating and free cash flows.
- Recent financial filings indicate continued operational challenges and a decline in cash reserves.
- --
- # RATIONALES
- ```json
- Source documents mention dilution or offering risk.